<rdf:RDF
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:j.0="http://www.ddmore.org/ontologies/webannotationtool#"
    xmlns:j.1="http://www.pharmml.org/ontology/"
    xmlns:j.2="http://www.pharmml.org/2013/10/PharmMLMetadata#" > 
  <rdf:Description rdf:about="http://repository.ddmore.foundation//model/DDMODEL00000261">
    <rdf:type rdf:resource="http://www.pharmml.org/ontology/PHARMMLO_0000001"/>
    <j.2:model-tasks-in-scope rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0006001"/>
    <j.2:model-field-purpose rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0000036"/>
    <j.2:model-research-stage rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0006012"/>
    <j.2:model-modelling-question rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0006037"/>
    <j.0:model-implementation-conforms-to-literature-controlled rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Yes</j.0:model-implementation-conforms-to-literature-controlled>
    <j.0:model-origin-of-code-in-literature-controlled rdf:datatype="http://www.w3.org/2001/XMLSchema#string">No</j.0:model-origin-of-code-in-literature-controlled>
    <j.2:model-has-description rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Assessment of treatment efficacy in metastatic castrationresistant prostate cancer (mCRPC) is limited by the frequent development of nonmeasurable bone metastases. The count of circulating tumor cells (CTCs) is emerging as a promising surrogate marker, which could replace the widely used prostate-specific antigen (PSA). CTC kinetic monitoring during treatment could be used to predict treatment efficacy in patients with mCRPC. However, relationships between the kinetics of CTCs and PSA have never been assessed. We built a semimechanistic population model of CTC and PSA kinetics during treatment.</j.2:model-has-description>
  </rdf:Description>
</rdf:RDF>
